Glioblastomas (GBMs) are highly lethal brain tumors with extremely poor prognosis. The treatment of GBMs remains palliative due to therapeutic resistance. GBM displays striking cellular heterogeneity with a population of tumor-initiating cell (BTICs) or GBM stem cells (GSCs) at the apex of differentiation hierarchy. We previously demonstrated that GSCs promote therapeutic resistance, tumor angiogenesis and cancer invasion, indicating that therapeutic targeting of GSCs may effectively improve GBM treatment. The stem cell-like phenotype of GSCs is maintained by a set of core transcription factors including SOX2. The protein stability of SOX2 is tightly regulated by post-translational modifications. Our preliminary study indicated that SOX2 is regulated by both ubiquitylation (Ub) and deubiquitylation (Dub) in glioma cells. SOX2 is ubiquitylated by the E3 ubiquitin ligase, Huwe1, and then targeted for degradation in non-stem glioma cells. In GSCs, SOX2 protein is stabilized through deubiquitylation mediated by the deubiquitylase, HAUSP (Herpesvirus-Associated Ubiquitin-Specific Protease, also known as USP7). HAUSP is preferentially expressed in GSCs relative to neural progenitors. Targeting HAUSP by shRNA reduced SOX2 protein, promoted cell differentiation, disrupted GSC maintenance and potently inhibited GSC tumor growth. Functional inhibition of HAUSP by a small molecule inhibitor also inhibited tumor growth in orthotopic GBM xenografts and sensitized GSCs to radiation or temozolomide (TMZ). Based on these preliminary data, we hypothesize that HAUSP-mediated deubiquitylation antagonizes Huwe1-mediated ubiquitylation to stabilize SOX2 in the maintenance of GSCs, presenting a therapeutic target strategy to disrupts GSCs and suppress GBM tumor growth. We propose the following specific aims: 1. Determine the therapeutic impact of HAUSP inhibition on suppressing GBM tumor growth. 2. Define the molecular mechanisms underlying HAUSP-mediated GSC maintenance. 3. Evaluate synergy of HAUSP inhibition and current GBM therapies. The goal of this proposal is to evaluate the therapeutic potential of HAUSP inhibition in a preclinical study. We will determine whether targeting HAUSP can serve as an effective therapeutic strategy to improve GBM treatment. The proposed studies will lay a solid foundation for the development of novel anti-GSC therapeutics to effectively improve the survival of GBM patients.
Glioblastoma (GBM) is among the deadliest of all cancers and is highly resistant to conventional therapies, indicating that more effective therapeutics is urgently needed. We previously demonstrated that GBM stem cells (GSCs) promote therapeutic resistance and tumor growth, suggesting that targeting GSCs may effectively improve GBM treatment. GSCs are maintained by a set of core regulators including SOX2. We recently identified a critical deubiquitylating enzyme called HAUSP that stabilizes SOX2 protein to maintain the GSC phenotype. HAUSP inhibition reduced SOX2 protein, disrupted GSC maintenance, and potently inhibited tumor growth. Targeting HAUSP by a small molecule inhibitor also disrupted GSC tumor growth and sensitized GSCs to radiation or temozolomide (TMZ), suggesting that HAUSP is a potential therapeutic target. In this proposal, we will evaluate the therapeutic efficacy of targeting HAUSP in a preclinical study and determine whether HAUSP inhibition can serve as an effective strategy to improve GBM treatment. We expect that the proposed studies will lay a solid foundation for the development of novel anti-GSC specific therapeutics to improve the survival of GBM patients.
